Guess we're really lucky to have brought Nadia on board to deal with the FDA and Steven to be a deal maker, to say nothing of Peter's leadership overseeing the entire process. NOT!

If I was a conspiracy theorist the first thing I'd do is check all three of their overseas bank accounts, mainly because the three of them have overseen a game changing way of treating cancers and allowed it to be taken out of the equation when those suffering from cancer have survival choices to make.

But, then again, maybe the extremely significant attributes of MultiTAAs are just smoke, along with the once very promising vaccines of Tapimune. In that case, they've done great job of keeping stock at 1.50, but does anyone really think this is true?

Tens of billions of dollars are at stake and many big pharma companies will lose if MRKR succeeds, companies that can place tremendous pressure on the FDA to make sure that doesn't happen. So what's a payoff of 10 million or 20 million to ensure MRKR fails, drop in the bucket to them.

This is what can happen when you're too big to succeed, and MRKR was on the verge of being exactly that prior to the FALL.

Congressman John Lewis also announced he has stage 4 PC, will fight it with new effective drugs that have greatly reduced side effects.

Damn the good news, everytime we're informed of something positive regarding MRKR and/or TPIV the share price goes down.

Gotta be a heck of a tailwind to move the share price upward when we're dragging 5m shorts determined to prevent it.

Yep, knew that, just wondering about MultiTAA trials and if there is any possible reason for not getting those designations?

Why hasn't MultiTAA received orphan and/or fast track designation from the FDA? There are many drugs with such designations that don't have nearly the proven successes of MRKR yet as far as I know we haven't received either.

Does anyone know if MRKR has applied to the FDA for these, and if so what could possibly be the reasons for denial? Couldn't be denied under the qualifications for acceptance which MultiTAAs easily fulfills, so is there some other reason for MRKR to not receive these designations?

If I'm way off base and missing something here then I apologize for wasting your time, just seems slow walking MultiTAAs thru the process doesn't benefit anyone except those shorting the stock.

Good to see Peter step up, I for one didn't know what to expect.

Not exactly what I had in mind.

But, it's all set up for Peter to drop a bomb on shorts or one on investors.

Unfortunate that a bomb on shorts will require great news, while a bomb on investors only requires another of Peter's ambiguous presentations.

I don't know what that means, but I do know tomorrow should be a very interesting trading day.

Well, here we go again, investors looking forward to presentations that will expound upon the many advantages that MRKR offers with TPIV vaccines and MultiTAAs.

Or, investors dreading the presentations by Peter will downplay those advantages and instead provide ammo for shorts to once again drive down share price.

It's a shame when investors doing their DD have to look beyond the proven successes of this science, and instead take into consideration that the CEO MIGHT downplay those successes to the point where share price is once again negatively affected.

Since Peter's no fool, I'm sure he realizes the effect his previous presentations have had on share price, and what he says moving forward will once again be critical. Up to this point I've been long and optimistic where the science is concerned, but if Peter uses these presentations to present a soso, ambiguous preview of MRKR's future then I'll have to consider if this company is a viable investment with him as CEO.

Seems like the perfect time for a pair of presentations that will expound on the successful trials being conducted on both TPIV vaccines and MultiTAAs.

Conversely, Peter has proven he has the ability to pull defeat from the jaws of victory.

Too bad this didn't come from Kim months ago, we wouldn't be sitting at .18 without any idea of what Kim has in mind moving forward.

We still have 5m short shares to deal with that aren't going to allow a rise in share price unless Peter delivers great news, anything short of that will result in another drop.

Since leaks from within MRKR seem to dictate how shorts react to these presentations, I would guess that the next week before presentations should tell us pretty much what Peter is going to say. How sweet it would be for Peter to surprise everyone with news of a buyout, or another pancreatic CR, or simply a extremely positive outlook for on-going trials.

Peter has thus far failed miserably to instill any confidence in investors that he can or will deliver a presentation that won't result in continued shorting of the stock. There's reasons why we're around $6 down in share price, and Peter has to accept responsibility for his part in not turning it around.

Hopefully these two presentations will turn the tide and Peter will present MRKR as we view it, being THE most innovative and competitive company in new cancer treatments.

Whew, thought maybe shorts let us know what they know for a change and nobody told me.

OMG, everybody cashed out and left me all alone, apologize if it was something I said! NOT!!!

I can't believe he hasn't trolled the net and found out about MRKR all by himself, I sure as hell would have in his position.

Know how you feel, but that kind of thinking could lead to a mistake as bad as not cashing out at $9.

Just feel it's all good, Nadia and Steven are going to do their thing and hopefully Peter doesn't screw up what they're trying to accomplish.

Very quiet, everyone must be sleeping until it's over $20.

Would love to see a substantial buyout of some kind, if nothing else to mitigate the influence shorts have had on this stock for the last 4 months. This is getting old real fast, and with the massive short shares still there, there's no telling what their end game might be.

But the science is proving to be almost too good to fail, just hope MRKR management proves to be as well.

Well put, Micro, hope it doesn't offend you but I couldn't have said it better myself!

Although I hate to say it, in my opinion it would have to be the 2nd coming of Christ for Peter to make it sound positive, so it had better be GREAT NEWS.

Being optimistic one might hope Nadia and Steven having been earning their salary, where a buyout not affected by share price is imminent.
Your run-down of MRKR's advantages, while impressive, doesn't even take into consideration of TPIV vaccines including Polystart. Added together I would assume MRKR would be very attractive to a variety of big pharma companies.

Meanwhile, were down to 2.75 and I'm still buying so what do I know!

Peanuts compared to the billions that are at stake, both to MRKR and big pharma affected by the science, means nothing!

Feel for your predicament, every investor in MRKR is in a similar position, and how each responds will be based on their own personal situation.

You're right, share price tells the story, and that is a very successful short attack that started with the pc fiasco and continues to this day. It has little to do with the science and much more to do with greed, though the questionable complicity of management has certainly made the attack far more successful than it should have been.

Not gonna give any "cheerleader posts", you invested in the science as we all did, and have been blindsided by this share drop. Getting out now is a tough call, some investors are doing exactly that while others are buying, guess we'll find out soon enough who is right.

Come on shorts, do your best, you may be tanking our share price but we're gonna spellcheck you to death.

Well good for you, looks like you found a stock where management actually cares what the share price means to investors as well as the company.

Now I don't think MRKR management isn't aware or doesn't care about share price, but what they apparently weren't aware of at the release of pc data and still remain ignorant of is the effect that 5m short interest can have on sp.

Regardless of how Peter intended the cc to be perceived, it was interpreted by many investors as both a failure of the science and incompetence by the company. The fact it was neither seems to be buried in the weeds by some investors, right along side of all the positive facts that actually surround MRKR trials.

Well, haven't we turned into a bunch of snobs, misspellings and bad English are commonplace on this board so why the big deal with Keith?

Investors would be far better off concentrating on falling share price and the science, and try to decide what the hell is going on and if you're listening to the right people rather than hold English class.

Management has overseen a $6 dollar drop in share price, so if they're all in the lab developing product to market then and no one cares about the share price then I guess that would make sense. But we all know that isn't the case, Peter's not in the lab nor Nadia nor Steven and they have some of the best minds in cancer to advise them.

Now we're below $3 and apparently for some that's where we belong, well for Keith that's not good enough and for me either. Since the science is outstanding on many different levels, effectiveness, delivery, cost, ability to piggyback drugs, etc., how could we have fallen so far so fast after the impressive pancreatic data release?

Hate to say it, but I am one benefiting from this fall because buying below $3 is too good to pass up. But others are benefiting in other ways, so investors should take care before making any decisions based on posts, including this one.

I think your opinion is pretty much shared by most of the longs, and certainly by a majority of brokers. I will also add today, don't know what management will do to alleviate the downward pressure on share price but the opportunity to buy at these prices are just too good to pass up.

Yep, seen that, and it's a shame. But doesn't take a whole lot of short pressure to drive stock down when investors start questioning the science itself, much less the reliability of data of ongoing trials.

But when you start from a position of MRKR management being virtually silent since the pc release, then a cc that leaves investors questioning whether the entire science is flawed, then you reap what you sowed.

Yep, it's a shame, but it's only money to us where it's life and death to millions of cancer patients if this continued attack on MRKR delays or eliminates FDA approval of their treatments.

I'm long on MRKR and still as confident as ever in the science, it's simply a shame this could happen again.

Sad, but there are a whole lot of people out there that want MRKR to fail, and of course it all comes down to greed. It just floors me that with the quality of people we've got in management, nobody noticed the event that started the Fall was being recreated once again with 5m short interest just needing a reason and let Peter give it to them.

So while it's unfortunate for them that we have the science, it's unfortunate for us that we have Peter. It's a hell of a thing when investors are selling shares so low when great news is coming in from a variety of sources, but that is what we have. The ONLY thing that concerns me is what management is going to do moving forward, we certainly can't afford another cc by Peter.

While the share price is certainly disturbing, the science remains the same. As long as that continues to progress successfully, time is the only factor keeping a massive amount of shorts still around.

As positive trial data comes in, the pps will skyrocket and/or buyouts will most likely happen. Any day a announcement of a buyout might occur, either with TPIV vaccines or MultiTAAs or the entire MRKR company.

But I'm pretty sure shorts will know before us, and act accordingly.

Yep, you're right, learned that a while ago, but the expertise and connections some have on this board is really a plus for investors. Just have to be a hell of a lot more diligent when processing the information being presented, we may be on the same team but only some are continuing to profit from this fall.

Read on other boards of bragging that investors are making real good money renting shares to be shorted, let that be a lesson to us.

Do your own DD, being influenced by previously trusted investors could cost your investment. I don't blame them for making money, but I do condemn them when they attempt to influence others simply to keep the share price down for their own gain.

Just saying...

Right there with you lumpy!

Whether it be this or another company offering a buyout, the clock is still ticking on shorts.

TPIV vaccines, including Polystart, added to MultiTAA makes MRKR the absolute leader in innovative treatments for cancer. The fact their delivery system is safe and virtually non-invasive is huge on it's own, being able to piggyback drugs directly to tumors is huge and let's not forget the drastic drop in price.

There are so many positives coming from these trials that are proving the science, there's no way buyouts aren't being addressed in the boardrooms of big pharma.

As with you, ALL in my opinion and with hope!

Makes one wonder what today's meeting at MRKR was like, was everyone on board with Peter's assessment of their accomplishments and potentials moving forward? Did nobody raise the issue of 5m short interest, what affect that had on the pancreatic data release thus what was needed to avoid another fiasco?

Forgive me, but the hires of Nadia and Steven immediately following the pc release somehow convinced me that they were hired to avoid any such lack of information, that it would never be a issue again. Apparently that thinking was mistaken.

So, bottom line shorts have a firm grip on MRKR stock, supported this time around intentionally or not by Peter's cc, but that ship has sailed. We can't have this kind of performance again, especially when shorts seem well aware what the contents will be long before investors.

Science is great, management is not, don't know how they can look at their salaries and justify what is happening to those that have invested in MRKR.

I'll go out on a limb here and declare that 66 patients with triple negative breast cancer are thrilled with the results of treatment with TPIV 200.

Wonder how they feel, along with women currently suffering from the disease, that successful treatments with TPIV 200 mean so little to investors. That their future is being compromised by greed, pure and simple, with no recourse other than to wait and pray that MRKR continues to proceed with trials unencumbered by financial losses.

Yeah, but what really happened? MRKR asked to clear up some paperwork, which happens frequently with the FDA, so that causes the stock to tank? Or was it the ovarian trial that apparently had little chance for success, to be discontinued in 2020 after a full data review.

This is pretty much the pancreatic fiasco all over again, nothing really negative but a half-assed effort to find anything positive, bringing the full wrath of 5m shorts.

By the way, the breast cancer data was really outstanding, my words not Peter's.

Doesn't sound like it's failed yet, it just didn't meet something called the threshold of probability for success according to pre-determined criteria, or something like that. That statement most probably takes more into consideration far more than simply the rate of patient success.

But they haven't dropped the trial yet, and only will after a full data review in FQ 2020, so it's far from the shredder.

Besides, maybe the share price has effected trials and this study may be placed on the back burner for now.

But, what the hell do I know, I'm invested right along with you in a stock where the CEO seems determined to trash it.

I can also see them coming soon for the TPIV vaccines, and that includes Polystart.

Nothing has changed other than the share price, MultiTAA science is still there and along with the vaccines make MRKR a extremely valuable company.

All the noise concerning the delay of the AML P2 is just that, noise, and why it is being given such detrimental status is telling in itself.

More likely counting his money...

But, not to worry, MRKR has class people in place and a science unmatched by any other.

Peter is another matter altogether, hopefully he acted on his own.

Ever heard of "too big to fail"?

My fear is MRKR is "too big to succeed".

Billions are at stake right now to big pharma, tens of billions looking down the road, and that kind of money buys all kinds of greedy behavior whether legal or not. By current investors or not.

PL's right, something smells here and it pisses me off too.

I feared a mundane cc and that's exactly what Peter presented. It gave shorts the ammo needed to immediately declare the sky is falling, while downplaying any role TPIV vaccines might play in MRKR's future.

I don't know why it was presented that way, but once again MRKR gave the shorts what they NEEDED and what we feared. What Peter couldn't do is take away the science itself, that remains solid regardless of the negative context of the cc.